Abiomed Appoints New Chief Financial Officer

Abiomed Inc., a provider of breakthrough heart support technologies, has appointed Todd A. Trapp as vice president and chief financial officer (CFO), effective April 9.
 
Trapp, 47, joins Abiomed from Watts Water Technologies Inc., where he served as CFO since 2015. Watts Water Technologies is a $1.5 billion global manufacturing leader of products to control the efficiency, safety, and quality of water within residential and commercial applications. Prior to joining Watts Water Technologies, Trapp spent 13 years in a variety of financial and operational roles at Honeywell International Inc., a $40 billion diversified technology and manufacturing company. At Honeywell, Trapp served as vice president of Financial Planning and Analysis, CFO of the Airlines Business Unit, director of Finance for the Transportation Systems Division, investor relations manager, and other senior finance positions. Prior to joining Honeywell, Trapp held several treasury and finance operational roles at United Business Media Inc. and Pearson Inc.

Trapp has a bachelor of science degree in accounting from Providence College and an MBA in finance from Northeastern University.
 
“I am very excited to join Abiomed, a company that has and continues to revolutionize patient care with its world class Impella technology,” said Trapp. “I am committed to working closely with the employees and shareholders to further grow the company and continue Abiomed’s tradition of strong execution.”
 
“After an extensive search, we are pleased to welcome Todd Trapp to our executive team at Abiomed,” said Michael R. Minogue, chairman, president and CEO of Abiomed. “Todd’s proven record of accomplishment as a global CFO exemplifies his financial expertise, operational discipline and leadership. Todd will help Abiomed rise to the next level for the patients that we serve and our shareholders.”
 
The Impella 2.5, Impella CP, Impella 5.0 and Impella LD are U.S. Food and Drug Administration (FDA)-approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed’s right-side heart pump, the Impella RP device, is FDA approved to treat patients experiencing acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.